The risk factors for mortality of community-acquired pneumonia in Japan

By Fujiki Rei   Kawayama Tomotaka   Ueyama Toshihiko   Ichiki Masao   Aizawa Hisamichi  

Journal of Infection and Chemotherapy, Vol. 13, Iss. 3, 2007-06 ,pp. : 157-165

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study*

By Réa-Neto Álvaro   Niederman Michael   Margareth Lobo Suzana   Schroeder Eric   Lee Michael   Kaniga Koné   Ketter Nzeera   Prokocimer Philippe   Friedland Ian  

Current Medical Research and Opinion, Vol. 24, Iss. 7, 2008-07 ,pp. : 2113-2126

Informa Healthcare

Access to resources Recommend Favorite

Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan

By Kohno Shigeru   Yanagihara Katsunori   Yamamoto Yoshihiro   Tokimatsu Issei   Hiramatsu Kazufumi   Higa Futoshi   Tateyama Masao   Fujita Jiro   Kadota Jun-ichi  

Journal of Infection and Chemotherapy, Vol. 19, Iss. 6, 2013-12 ,pp. : 1035-1041

Springer Publishing Company

Access to resources Recommend Favorite

Community-acquired pneumonia

By Wyndham Mike  

Community Practitioner, Vol. 79, Iss. 4, 2006-04 ,pp. : 113-113

Community Practitioner

Access to resources Recommend Favorite

Efficacy of serum procalcitonin in evaluating severity of community-acquired pneumonia in childhood

By Don Massimiliano   Valent Francesca   Korppi Matti   Falleti Edmondo   De Candia Alessandro   Fasoli Lolita   Tenore Alfred   Canciani Mario  

Scandinavian Journal of Infectious Diseases, Vol. 39, Iss. 2, 2007-01 ,pp. : 129-137

Informa Healthcare

Access to resources Recommend Favorite